Kyntra Bio Adds Biotech Finance Veteran to Board Amid Pipeline Push…

Event summary

Andrew E. Singer, MBA, joins Kyntra Bio's Board of Directors as an independent director and Audit Committee member effective October 1, 2026.
Maykin Ho, Ph.D., steps down from the Board after nearly eight years of service, effective September 30, 2026.
Singer brings 25+ years of biotechnology finance and strategy experience, including roles at Credit Suisse, Wells Fargo, and Epizyme.
Kyntra Bio focuses on advancing its rare disease and oncology pipeline, including roxadustat for anemia and FG-3246 for prostate cancer.

The big picture

Kyntra Bio's appointment of Andrew E. Singer reflects a strategic shift towards leveraging deep biotech finance experience to navigate its pipeline advancements. The move comes as the company sharpens its focus on rare disease and oncology therapies, amid a competitive landscape where financial acumen and corporate governance are critical. Singer's background in capital formation and strategic transactions could be pivotal as Kyntra Bio evaluates its development plans and seeks to create long-term value.

What we're watching

Pipeline Execution: How Kyntra Bio will advance its Phase 3 trial of roxadustat in LR-MDS and Phase 2 development of FG-3246 for prostate cancer.
Financial Strategy: Whether Singer's expertise will help strengthen Kyntra Bio's financial position and capital formation efforts.
Governance Impact: The pace at which the new board composition influences strategic decisions and corporate development.